JPH09509428A - 薬理学的に活性な薬剤の血清半減期を増加させるための方法および組成物 - Google Patents

薬理学的に活性な薬剤の血清半減期を増加させるための方法および組成物

Info

Publication number
JPH09509428A
JPH09509428A JP7522373A JP52237395A JPH09509428A JP H09509428 A JPH09509428 A JP H09509428A JP 7522373 A JP7522373 A JP 7522373A JP 52237395 A JP52237395 A JP 52237395A JP H09509428 A JPH09509428 A JP H09509428A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
transthyretin
ligand
composition according
pharmacologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7522373A
Other languages
English (en)
Japanese (ja)
Inventor
ジェフリー エム． ブラニー，
フレッド コーヘン，
Original Assignee
カイロン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイロン コーポレイション filed Critical カイロン コーポレイション
Publication of JPH09509428A publication Critical patent/JPH09509428A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP7522373A 1994-02-23 1995-02-13 薬理学的に活性な薬剤の血清半減期を増加させるための方法および組成物 Pending JPH09509428A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20038794A 1994-02-23 1994-02-23
US08/200,387 1994-02-23
PCT/US1995/001815 WO1995022992A2 (en) 1994-02-23 1995-02-13 Method and compositions for increasing the serum half-life of pharmacologically active agents

Publications (1)

Publication Number Publication Date
JPH09509428A true JPH09509428A (ja) 1997-09-22

Family

ID=22741505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7522373A Pending JPH09509428A (ja) 1994-02-23 1995-02-13 薬理学的に活性な薬剤の血清半減期を増加させるための方法および組成物

Country Status (7)

Country Link
US (1) US5714142A (es)
EP (1) EP0802798A1 (es)
JP (1) JPH09509428A (es)
AU (1) AU1843295A (es)
CA (1) CA2184002A1 (es)
MX (1) MX9603570A (es)
WO (1) WO1995022992A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529108A (ja) * 2002-04-04 2005-09-29 アムジエン・インコーポレーテツド 薬理学的活性ペプチド／タンパク質の血清中半減期を上昇させるためのトランスサイレチンペプチド／タンパク質融合物の使用

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5727798A (en) * 1996-12-23 1998-07-17 Texas A & M University, The Anti-amyloidogenic agents
US6506798B1 (en) 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
GB9824632D0 (en) * 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
CA2370653A1 (en) * 1999-04-26 2000-11-02 Albert Burger Pharmaceutical compositions of tetrac and methods of use thereof
US6740680B1 (en) * 1999-04-26 2004-05-25 Becton Pharma, Inc. Pharmaceutical compositions to tetrac and methods of use thereof
US6656730B1 (en) * 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US6887842B1 (en) * 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
EP1339702A1 (en) 2000-03-15 2003-09-03 Warner-Lambert Company 5-amide substituted diarylamines as mek inhibitors
FI107018B (fi) * 2000-04-06 2001-05-31 Ipsat Therapies Oy Dermatologinen käyttö ja valmiste
EP1399484B1 (en) * 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
US6924376B2 (en) 2002-04-17 2005-08-02 Cytokinetics, Inc. Compounds, compositions and methods
US6949538B2 (en) * 2002-07-17 2005-09-27 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005539062A (ja) * 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2005042697A2 (en) * 2003-10-06 2005-05-12 Cytokinetics, Inc. Compounds, compositions and methods
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
EP1912946B1 (en) * 2005-07-20 2009-05-27 Eli Lilly And Company Pyridine derivatives as dipeptedyl peptidase inhibitors
WO2007015807A1 (en) * 2005-07-20 2007-02-08 Eli Lilly And Company Phenyl compounds
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
CA2667678A1 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
EP2162540A2 (en) 2007-05-22 2010-03-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
CN102015606B (zh) 2007-06-08 2015-02-04 满康德股份有限公司 IRE-1α抑制剂
US20090131380A1 (en) * 2007-11-16 2009-05-21 Pekka Heino Novel pharmaceutical composition for topical treatment of skin psoriasis and the treatment method thereof
MX347291B (es) 2009-03-20 2017-04-17 Amgen Inc Inmunoglobulinas portadoras y usos de las mismas.
EA201370076A1 (ru) 2010-09-22 2013-08-30 Амген Инк. Иммуноглобулины-переносчики и их применение
CA2828405A1 (en) 2011-02-28 2012-09-07 Istituto Di Ricovero E Cura A Carattere Scientifico Materno-Infantile Bu Rlo Garofolo - Ospedale Di Alta Specializzazione E Di Rilievo Nazionale Apoptosis-inducing molecules and uses therefor
US9340590B2 (en) 2011-03-16 2016-05-17 Amgen Inc. Potent and selective inhibitors of NaV1.3 and NaV1.7
CA3062003C (en) 2012-05-17 2022-01-11 Extend Biosciences, Inc. Vitamin d as a targeting group for therapeutic peptides
EP2908849B1 (en) * 2012-08-31 2019-04-17 Board Of Regents, The University Of Texas System A method to improve pharmacokinetics of drugs
US9029342B2 (en) 2012-09-17 2015-05-12 Board Of Regents Of The University Of Texas System Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof
WO2014099984A1 (en) 2012-12-20 2014-06-26 Amgen Inc. Apj receptor agonists and uses thereof
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
CA2951391C (en) 2014-06-10 2021-11-02 Amgen Inc. Apelin polypeptides
EP3179857B1 (en) 2014-08-14 2021-09-08 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US20190382462A1 (en) 2017-01-13 2019-12-19 Pietro P. Sanna Methods and compositions for treating hpa hyperactivity
US20210346513A1 (en) 2017-08-04 2021-11-11 Amgen Inc. Method of conjugation of cys-mabs
FR3113904B1 (fr) 2020-09-08 2022-08-12 Innoverda Procédé de synthèse du 3,5-diiodo-4-hydroxy benzylalcool

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410633A (en) * 1980-09-25 1983-10-18 Corning Glass Works Method for the measurement of free thyroxine or 3,5,3'-triiodothyronine in a liquid sample
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers
SE509359C2 (sv) * 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5273885A (en) * 1992-07-31 1993-12-28 Syntex (U.S.A.) Inc. Conjugates of monophenyl thyroid analogs useful in assays

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005529108A (ja) * 2002-04-04 2005-09-29 アムジエン・インコーポレーテツド 薬理学的活性ペプチド／タンパク質の血清中半減期を上昇させるためのトランスサイレチンペプチド／タンパク質融合物の使用

Also Published As

Publication number Publication date
MX9603570A (es) 1997-03-29
EP0802798A1 (en) 1997-10-29
CA2184002A1 (en) 1995-08-31
US5714142A (en) 1998-02-03
WO1995022992A2 (en) 1995-08-31
WO1995022992A8 (en) 2002-02-14
AU1843295A (en) 1995-09-11

Similar Documents

Publication Publication Date Title
JPH09509428A (ja) 薬理学的に活性な薬剤の血清半減期を増加させるための方法および組成物
WO1995022992A1 (en) Method and compositions for increasing the serum half-life of pharmacologically active agents
He et al. Aptamer‐protac conjugates (apcs) for tumor‐specific targeting in breast cancer
EP1436011B1 (en) Dendrimers for use in targeted delivery
Okuda et al. Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration
CN104524596B (zh) 经修饰的大分子
Brinkhuis et al. Size dependent biodistribution and SPECT imaging of 111In-labeled polymersomes
Lim et al. Biodegradable, endosome disruptive, and cationic network-type polymer as a highly efficient and nontoxic gene delivery carrier
US6492560B2 (en) Discrete-length polyethylene glycols
Hosseinkhani et al. Dextran–spermine polycation: an efficient nonviral vector for in vitro and in vivo gene transfection
CN101700401B (zh) 具有用于共轭生物活性化合物的部分的聚亚烷基二醇
AU682308B2 (en) Self-assembling polynucleotide delivery system
US7812051B2 (en) Pharmaceutical compositions of β-lapachone and β-lapachone analogs with improved tumor targeting potential
US6521736B2 (en) Amphiphilic polymeric materials
Khandare et al. Novel polymeric prodrug with multivalent components for cancer therapy
JP2010539245A (ja) 薬物担体
PL196533B1 (pl) Sposób stopniowego przyłączania ugrupowań poli (glikolu etylenowego) (PEG) szeregowo do polipeptydu
JP2002508400A (ja) アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
CN101400730A (zh) 使用自组装两性聚合物增溶和靶向递送药物
BRPI0712013A2 (pt) preparaÇço de conjugados polimÉricos de compostos terapÊuticos, agrÍcolas e aditivos alimentares
Taori et al. Structure–activity examination of poly (glycoamidoguanidine) s: glycopolycations containing guanidine units for nucleic acid delivery
US20190117680A1 (en) Dendrimeric platform for controlled release of drugs
JP2002526456A (ja) カチオン性化合物およびマクロ分子担体としてのそれらの使用
Shcharbin Practical guide to studying dendrimers
Jin et al. Poly (ethylene glycol) prodrug for puerarin and its characteristic evaluation